Pantheon Vision Secures a Second Tranche of Funding to Advance Bioengineered Corneal Implants

Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants, announced the closing of $1.8 million in a second tranche from KeraLink International (KLI). This comes following a previous $2.5 million investment from KLI last year, bringing the total funding to $4.3 million. The funds will be used to advance Pantheon Vision’s development of bioengineered corneal implants to reduce reliance on donated corneal tissue.

Pantheon Vision is creating bioengineered corneal implants to reduce reliance on donated corneal tissue, which is often unavailable in low- and middle-income countries. The company said it plans to engage the FDA in the coming months to guide plans for global product development.

“The additional funding from KLI positions Pantheon Vision to advance our bioengineered corneal implants to treat corneal blindness,” said John Sheets, President and CEO, Pantheon Vision. “We are grateful for the support from KLI, which shares our passion for finding alternative solutions for curing corneal blindness globally.”